FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL								
OMB Number: 3235-02										
l	Estimated average burden									
l	hours per response:	0.5								

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>THERO JOHN F</u>						2. Issuer Name and Ticker or Trading Symbol AMARIN CORP PLC\UK [AMRN]							(Check all applicab X Director		10% Owner		ner	
(Last) (First) (Middle) C/O AMARIN PHARMA, INC. 440 US HIGHWAY 22					3. Date of Earliest Transaction (Month/Day/Year) 02/28/2020								below)	Officer (give title below) President and CEO				
(Street) BRIDGEWATER NJ 08807					4. If Amendment, Date of Original Filed (Month/Day/Year)								ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(5	State)	(Zip)															
1. Title of Security (Instr. 3) 2. Trans. Date					-			3. Transaction Code (Instr. 8) 4. Securities Act Disposed Of (D)			ies Acquire	d (A) or	5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership	
									v	Amount	Amount (A) or (D)		Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)	
Ordinary Shares ⁽¹⁾					3/2020			M ⁽²⁾		6,736 A		(3)	2,679,007		D			
Ordinary Shares ⁽¹⁾ 02/2					/2020		M ⁽²⁾		6,736 A		(3)	2,685,743		D				
Ordinary Shares ⁽¹⁾					3/2020		F ⁽⁴⁾		5,302 D		\$14.67	2,680	2,680,441 ⁽⁵⁾		D			
			Table II - I							osed of, onvertib			Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Dat if any (Month/Day/Ye	Cod	nsactior de (Instr	Derivativ Securitie Acquired Dispose	Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4		6. Date Exercis Expiration Date (Month/Day/Ye		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported Transacti	ive ties cially ing ed	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	ion(s)			
Restricted Stock Units ⁽⁶⁾	\$0.00	02/28/2020		М			6,736	(2)		(3)	Ordinary Shares ⁽¹⁾	6,736	\$0.00	121,2	49	D		
Restricted Stock Units ⁽⁶⁾	\$0.00	02/28/2020		M			6,736		(2)		Ordinary Shares ⁽¹⁾	6,736	\$0.00	\$0.00 121,2		D		
Restricted Stock Units ⁽⁶⁾	\$0.00	03/02/2020		A		178,100		(7)		(3)	Ordinary Shares ⁽¹⁾	178,100	\$0.00	178,100		D		

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 970,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net total revenue for 2019 exceeding \$400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The eighteenth vesting event occurred on February 28, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches.
- 4. Represents withholding by the Issuer of shares in respect of tax liability incident to the vesting of a security issued in accordance with Rule 16b-3, and not a market sale of securities.
- 5. Please see the section titled "Remarks" below for additional information
- 6. Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion.
- 7. On March 2, 2020, the Reporting Person was granted 178,100 RSUs under the Plan. These RSUs vest in three equal installments on each of February 28, 2021, February 28, 2022 and February 28, 2023.

Remarks:

As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 9,756,404 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs granted under the Plan, including but not limited to certain performance-based RSUs that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time

/s/ John F. Thero

03/03/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.